Aegerion Pharmaceuticals Inc (AEGR)

pos +0.10
Today's Range: 1.86 - 2.34 | AEGR Avg Daily Volume: 537,900
Last Update: 11/29/16 - 4:00 PM EST
Volume: 2,168,985
YTD Performance: -80.50%
Open: $1.89
Previous Close: $1.87
52 Week Range: $1.23 - $20.45
Oustanding Shares: 29,545,088
Market Cap: 58,203,823
6-Month Chart
TheStreet Ratings Grade for AEGR
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 0 0 0 0
Moderate Buy 0 0 0 0
Hold 2 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 3.00 3.00 3.00 3.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -0.31
Price Earnings Comparisons:
AEGR Sector Avg. S&P 500
-0.31 0.00 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
20.12% -81.17% -97.22%
Revenue 51.50 0.00 0.00
Net Income 0.00 0.20 0.00
EPS 0.00 0.00 0.00
Earnings for AEGR:
Revenue 0.24B
Average Earnings Estimates

Earnings Estimates data is not available for AEGR.

Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands

bullishAegerion Pharmaceuticals upgraded at Jefferies

Jul 28, 2015 | 7:05 AM EDT

AEGR was upgraded to Buy from Hold, Jefferies said. $26 price target. Positively skewed risk/reward.

bearishAegerion downgraded at Jefferies

Oct 31, 2014 | 7:35 AM EDT

AEGR downgraded to Hold from Buy, said Jefferies. Price target cut from $61 to $24 on huge earnings miss and downward guidance. 

bearishAegerion downgraded at Deutsche Bank

Oct 31, 2014 | 6:59 AM EDT

AEGR downgraded to Hold from Buy, said Deutsche. Company missed Q3 revenues and decreased guidance significantly. Management's ability to execute in question.


Robert Moreno

 | Oct 2, 2014 | 2:17 PM EDT

Charting setups in Myriad Genetics, Clovis Oncology and Aegerion Pharma.

bearishAegerion Pharmaceuticals price target lowered at Jefferies

Mar 28, 2014 | 8:03 AM EDT

AEGR cut its number, Jefferies said. Driven by lowered revisions on Juxtapid sales. $80 price target and Buy rating. 


Adam Feuerstein

 | Aug 1, 2013 | 12:38 PM EDT
It's time to review the mid-cap biotech stocks reporting second quarter results next week, says Adam Feuerstein, Sr. Columnist at TheStreet.

bullishAegerion Pharmaceuticals price target raised at J.P. Morgan

Jun 12, 2013 | 8:26 AM EDT

AEGR price target was raised to $88, J.P. Morgan said. Encouraging physician feedback and the recent approval recommendation for Lojuxta have improved the valuation outlook.

bullishAegerion Pharmaceuticals target raised at Jefferies

Dec 27, 2012 | 7:54 AM EST

Shares of AEGR now seen reaching $29, Jefferies said. Juxtapid approval. Buy rating.


Adam Feuerstein and Gregg Greenberg

 | Dec 14, 2012 | 5:30 AM EST
Adam Feuerstein, Sr. Columnist for TheStreet, says three big FDA drug approval decisions are the next big things to watch in biotech.
volatility is quite low here, and we could see some downsides here in the short...


News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.